Marché mondial des ingrédients oméga-3 pour les produits pharmaceutiques – Tendances et prévisions du secteur jusqu’en 2030

Analyse et taille du marché des ingrédients oméga-3 pour les produits pharmaceutiques

La sensibilisation croissante des consommateurs aux bienfaits liés à la consommation d'acides gras oméga-3 tels que le DHA et l'EPA est l'un des principaux facteurs favorisant la croissance du marché. De nombreuses études de recherche sont actuellement en cours, ce qui devrait créer un avantage concurrentiel pour plusieurs fabricants afin de développer de nouveaux ingrédients oméga-3 innovants pour les produits pharmaceutiques. L'augmentation des maladies liées au mode de vie et à l'âge en Amérique du Nord et en Europe améliore par conséquent la croissance du segment des suppléments et des aliments fonctionnels, avec une part de revenus de 52 %.

 Data Bridge Market Research analyse le taux de croissance du marché des ingrédients oméga-3 pour les produits pharmaceutiques au cours de la période de prévision 2023-2030. Le TCAC attendu du marché des ingrédients oméga-3 pour les produits pharmaceutiques a tendance à être d'environ 11,5 % au cours de la période de prévision mentionnée. Le marché est évalué à 733,5 millions USD en 2022 et devrait atteindre 1 752,4 millions USD d'ici 2030. En plus des informations sur le marché telles que la valeur marchande, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l'équipe de Data Bridge Market Research comprend également une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Portée et segmentation du marché des ingrédients oméga-3 pour les produits pharmaceutiques

Définition du marché

Les ingrédients oméga-3 sont des acides gras polyinsaturés naturels et des nutriments essentiels à une santé humaine optimale. Il existe trois types d'ingrédients oméga-3, à savoir l'acide eicosapentaénoïque (EPA), l'acide alpha-linoléique (ALA) et l'acide docosahexaénoïque (DHA). L'EPA et le DHA sont principalement extraits du poisson et l'ALA est principalement extrait de sources végétales telles que les graines et les noix.

Dynamique du marché mondial des ingrédients oméga-3 pour les produits pharmaceutiques

Conducteurs

• Demande croissante en acide docosahexaénoïque (DHA)

L'acide docosahexaénoïque (DHA) est de plus en plus demandé en raison de l'utilisation croissante du produit dans les préparations pour nourrissons pour l'amélioration de la santé globale du nourrisson. Dans l'alimentation humaine, le DHA est l'acide gras oméga-3 le plus vital et le plus abondant, qui contribue au maintien de la santé globale du corps humain. Le DHA est un composant principal du développement et de la maturité du cerveau et de la vue d'un nourrisson. De plus, il est largement utilisé dans les compléments alimentaires et les aliments enrichis. Il est également largement utilisé dans le traitement de la démence, des maladies coronariennes (CAD), du trouble déficitaire de l'attention avec hyperactivité et du diabète de type 2. Le DHA a contribué à augmenter la longévité et a également entraîné son utilisation dans les produits nutritionnels pour personnes âgées. Ainsi, ce facteur augmente la croissance du marché.

• Progrès technologiques croissants

Technological advancements and product innovation is anticipated to boost the market for omega 3 ingredients during the forecast period. For instance, DSM introduced new 3C technology to reinvigorate omega 3 supplements category on October 6, 2016. Furthermore, on June 9, 2015, Croda introduced Incromega DHA and approved by European Food Safety Authority (EFSA). Additionally, Royal DSM collaborated with Evonik to manufacture omega 3 fatty acid products from natural marine algae for animal nutrition on March 8, 2017. This innovation will allow the production of omega 3 fatty acids for animal nutrition without using fish oil. This factor improves the market growth.

Opportunities

• Huge growth in concentrated forms of algal omega-3 ingredients

New ultra-high concentrated omega-3 ingredients offer several benefits to consumers willing to pay a higher premium price for high-end products. Several suppliers are investing in the production of high concentrated algal omega-3 products, estimating increased demand to drive the sales. The market for concentrates has also been increasing, as more consumers become aware of the benefits of algal omega-3 and seek the benefits of higher doses. Several major companies are involved in omega-3 manufacturing that has started to strategically capitalize the existing business expansion opportunity.

• Rising Research Activities

Numerous research studies have developed a link between consumption of fatty fish and lowering of coronary heart diseases. For instance, fish oils are widely used as a supplement to balance the required dietary intake of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Furthermore, fish oil is normally recommended as a supplement product for people who suffer from myocardial infarction by the American Heart Association, World Health Organization (WHO), the National Heart Foundation of Australia and National Health and Medical Research Council (NHMRC). Thus, this factor helps to create much opportunities for the growth of the market.

Restraints/Challenges

• Side Effects of omega-3 ingredients

There are various side-effects associated with the omega-3 ingredients for pharmaceuticals. Effects such as burping, diarrhea, heartburn, joint pain, stomach pain or discomfort, vomiting, constipation, nausea. Thus, these adverse effects affect the growth rate by decreasing the adoption of omega-3. This impedes the market growth.

• Increasing Negative Consumer Perception About omega-3 ingredients

Negative consumer perception associated with the smell and taste of omega-3 ingredients is also anticipated to limit the growth of the market. These unstable fatty acids can damage through enzymatic or chemical oxidation to form compounds that give foods a fishy smell. Additionally, fresh fish oil has no fishy taste or smell, just like fresh fish. People feel hesitant to adopt for omega-3 ingredients. Thus, this hampers the market growth.

This omega-3 ingredients for pharmaceuticals market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the omega-3 ingredients for pharmaceuticals market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2021, Omega-3 related supplier GC Rieber VivoMega announced its plans to enhance  production amenities and storage tanks to accommodate more production in the upcoming years.
• In 2021, KD Pharma Group introduced Alga3, a sustainable, vegan omega-3 solution. KD Nutra's superior technology and production flexibility enable for a huge range of omega-3 concentrates.
• In 2021, AlgaeCytes Limited announced plans to build its first commercial plant in Dessau, Saxon-Anhalt, Germany. The plant will be owned and operated by the Company’s German subsidiary, AlgaeCytes Germany GmbH.

Global Omega-3 Ingredients for Pharmaceuticals Market Scope

The omega-3 ingredients for pharmaceuticals market is segmented on the basis of source, type, forms, therapeutic areas, population type, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Source

• Marine
• Plant

Type

• Docosahexaenoic Acid (DHA)
• Eicosapentaenoic Acid (EPA)
• Alpha-Linolenic Acid (ALA)

Forms

• Liquid
• Dry

Therapeutic Areas

• Cardiovascular Diseases
• Autoimmune Diseases
• Bone & Joint Disorders
• Neurological Disorders
• Ophthalmic Disorders
• Skin Health
• Cancer
• Others

Population Type

• Adults
• Children

Distribution Channel

• Direct
• Indirect

Omega-3 Ingredients for Pharmaceuticals Market Regional Analysis/Insights

The omega-3 ingredients for pharmaceuticals market is analyzed and market size insights and trends are provided by source, type, forms, therapeutic areas, population type, and distribution channel as referenced above.

The major countries covered in the omega-3 ingredients for pharmaceuticals market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for omega-3 ingredients for pharmaceuticals market throughout the forecasted period because of growing usage of pharmaceutical products that contains omega-3 ingredients for prevention of cardiovascular disease. The increasing demand for healthy food in North America because of the growing awareness increased foodborne diseases and increasing food industry is anticipated to drive the growth of this global market during the forecast period.

Asia-Pacific dominates the market because of the increase in consumer demand for plant-based omega-3 products. The growing significance of omega 3 DHA for the development of the infant nervous system, vision, and brain combined with the product’s ability to support long-term health is expected to drive market growth in the upcoming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Omega-3 Ingredients for Pharmaceuticals Market Share Analysis

The omega-3 ingredients for pharmaceuticals market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Omega-3 ingredients for pharmaceuticals market

Key players operating in the omega-3 ingredients for pharmaceuticals market include:

• Avestia Pharma (India)
• Novasep (France)
• AbbVie Inc. (U.S.)
• KD Pharma Group (Japan)
• BASF SE (Germany)
• Corbion (Netherlands)
• DSM (Netherlands)
• AstraZeneca (U.K.)
• GSK plc. (U.K.)
• Fresenius Kabi AG (Germany)
• Croda International Plc (U.S.)
• AMARIN CORPORATION (Ireland)
• ANI Pharmaceuticals, Inc. (U.S.)
• Epax (Norway)
• Strides Pharma Science Limited (Inde)
• Pharma Marine AS (Norvège)
• KinOmega Biopharm Inc. (Chine)
• Camber Pharmaceuticals, Inc. (États-Unis)

SKU-54549